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doi:10.1Objective: Aortic valve replacement using a tissue valve is controversial for patients younger than 60 years old.
The long-term survival in this age group, the expected event rates during long-term follow-up, and valve-related
complications are not clearly determined.
Methods: From January 2000 to December 2009, overall survival, valve-related events, and echocardiographic
outcomes were analyzed in all patients younger than 60 years of age, who underwent biologic aortic valve
replacement. Patients who received a Perimount Carpentier-Edwards pericardial tissue valve (n ¼ 103) were
selected and compared with a propensity matched group of 103 patients who received aortic valve replacement
using a mechanical bileaflet valve. The mean follow-up was 33 24 months (range, 2–120), and the mean age at
implantation was 50.6  8.8 years (bioprosthesis, 55  8.9 years; mechanical valve, 50  8.6 years; P ¼ .03).
Results: Survival was significantly reduced in patients after biologic aortic valve replacement (90.3% vs 98%;
P ¼ .038). Freedom from all valve-related complications (bioprosthesis, 54.5%; mechanical valve, 51.6%;
P ¼ NS) and freedom from reoperation (bioprostheses, 100%; mechanical valve, 98%; P ¼ NS) were compa-
rable in both groups. The average transvalvular mean (11.2  4.2 mm Hg vs 10.5  6.0 mm Hg, P ¼ .05) and
peak (19.9  6.7 mm Hg vs 16.7  8.0 mm Hg, P ¼ .03) gradients were greater after biologic aortic valve re-
placement. Regression of the left ventricular mass index was more pronounced after mechanical valve replace-
ment (118.5  24.9 g/m2 vs 126.5  38.5 g/m2; P ¼ NS). The echocardiographic patient–prosthesis mismatch
was greater at follow-up after biological aortic valve replacement (0.876  0.2 cm2/m2 vs 1.11  0.4 cm2/m2;
P ¼ .01). Oral anticoagulation was a protective factor for survival among the bioprosthetic valve patients
(P ¼ .024).
Conclusions: In the present limited cohort of patients younger than 60 years old, biologic aortic valve replace-
ment was associated with reduced mid-term survival compared with survival after mechanical aortic valve
replacement. Despite similar valve-related event rates in both groups, the better hemodynamic performance
of the mechanical valves and/or protective effect of oral anticoagulation seemed to improve the outcome.
The transcatheter valve-in-valve intervention as potential treatment of tissue valve degeneration should not
be considered the sole bailout strategy for younger patients because no evidence is available that this would
improve the outcome. (J Thorac Cardiovasc Surg 2012;144:1075-83)The current guidelines for aortic valve replacement (AVR)
recommend the insertion of a bioprosthesis in patients of
any age who are reluctant to receive lifelong warfarin or
who have major medical contraindications to anticoagulant
therapy.1Comparedwith previous recommendations, a clear
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The Journal of Thoracic and Carconsidered a major selection criterion. Thus, the use of bio-
prosthetic valves has markedly increased in the past decade
and has led to a substantial reduction of mechanical valve
implantations.2 This trend might be justified because an in-
creasing number of reports have described the improved
long-term durability of the most recent tissue valve models
with low rates of structural valve deterioration (SVD).3 In
addition, current advances in transcatheter valve technology
have made valve-in-valve implantation feasible.4-7 This
option opens new horizons to treat bioprosthetic valve
degeneration by way of percutaneous procedures and is
currently used by invasive cardiologists as an argument to
recommend biologic AVR for younger patients.
Nevertheless, biologic AVR in patients younger 60 years
old remains controversial, and the expected event rates for
surgical and valve-related complications have not beendiovascular Surgery c Volume 144, Number 5 1075
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EOAI ¼ effective orifice area index
MAPEs¼major adverse prosthesis-related events
PPM ¼ patient–prosthesis mismatch
SVD ¼ structural valve deterioration
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Dclearly determined for this subset of patients. In the present
study, we analyzed the clinical outcomes after biologic and
mechanical AVR in patients 60 years old or younger.METHODS
Setting and Study Population
A consecutive series of patients undergoing AVR from January 2000 to
December 2009 was identified from a prospectively compiled database and
screened for the following inclusion criteria: AVR at age 60 years or youn-
ger, isolated or with concomitant procedures such as coronary artery bypass
grafting, ascending or aortic root surgery, and mitral or tricuspid valve
repair. The exclusion criterion was additional valve replacement.
Only patients who received a stented Carpentier-Edwards xenopericar-
dial tissue valve (model 3000TFX and 3300TFX, Edwards Lifesciences,
Irvine, Calif) were selected. The control group included patients who re-
ceived mechanical bi-leaflet aortic valve replacement (St Jude Medical,
Minneapolis, MI, or ATS Medical, Plymouth, MI) during the same period.
These valves were chosen, because they are the most commonly used
implants at our institution.
In the setting of a retrospective study, we used propensity matching to
improve comparability and to reduce selection bias.8,9 The investigators
were kept unaware of the outcomes during the matching process (Figure 1).
The patient data were prospectively recorded in a computerized data-
base or retrieved from hospital charts. All patients provided written in-
formed consent to use the data for study purposes. Clinical follow-up
was conducted at our institution or through contact with the patients’ car-
diologist or general practitioner. In addition, routine echocardiographic
follow-up was performed for all patients. All patients were contacted for
a questionnaire survey.
The patients with a mechanical valve prosthesis postoperatively re-
ceived lifelong warfarin anticoagulation, with a target of the international
normalized ratio of 2.0 to 2.5. Patients with aortic bioprostheses received
lifelong aspirin only.
Statistical Analysis
A number of differences in patient characteristics precluded unadjusted
comparisons of outcomes. To reduce selection bias, we used propensity
matching to approximate a randomized trial.10 Of all preoperatively
known variables, we identified 9 factors potentially correlated with the
valve choice (P  .1 on bivariate analysis): pulmonary arterial hyperten-
sion, active endocarditis, coagulation disorder, cancer, instable hemody-
namic, emergency status, concomitant procedures, preoperative need for
antifibrinolytic agents, and preoperative need for inotropic drugs. These
potential confounders were included in the logistic regression model. A
propensity score was calculated for each patient by solving the resulting
propensity models for the probability of receiving a bioprosthetic valve.11
Using only the propensity score, the bioprosthetic valve patients were
matched with the mechanical valve patients by ‘‘greedy’’ matching.8 Pa-
tients with bioprosthetic valves whose propensity scores deviated more
than 0.1 from those with mechanical valves were considered unmatched
(Table 2).1076 The Journal of Thoracic and Cardiovascular SurContinuous normally distributed variables are presented as the mean 
standard deviation. Non-normally distributed continuous variables are pre-
sented as the median and interquartile range. A bivariate comparison was
performed in paired design, using the Wilcoxon signed-rank test or paired
Student’s t test, if appropriate. For categorical variables, we used the
McNemar test. Cumulative survival was estimated using the Kaplan-
Meier method. We used uni- and multivariate Cox proportional hazard
regression models that accounted for the matching to estimate the indepen-
dent effect of valve type, after adjustment for other suspected confounding
factors, including age, hypertension, renal failure, logistic European Sys-
tem for Cardiac Operative Risk Evaluation, American Society of Anesthe-
siologists classification, preoperative ejection fraction, valve replacement
for endocarditis, functional valve pathology, aortic stenosis, aortic insuffi-
ciency, concomitant coronary artery bypass grafting, New York Heart As-
sociation class, and aortic dissection. Effect is reported as the P value,
hazard ratio, and 95% confidence intervals. Two-tailed tests of significance
are reported.
Statistical analysis was performed using the Statistical Package for
Social Sciences, version 17.0, for Windows (SPSS, Chicago, IL) and
Stata11 (StataCorp, College Station, Tex).
Study Endpoints
The primary study endpoints included overall survival and cardiac-
related mortality, SVD (defined as reoperation for valve failure and/or pa-
tient–prosthesis mismatch [PPM]), determined by echocardiography as the
effective orifice area index (EOAI), and reoperation. Sudden, unexplained
death was considered cardiac-related mortality. The secondary endpoints
were echocardiographic follow-up (left ventricular ejection fraction, trans-
valvular gradients, and left ventricular mass and dimensions) and major ad-
verse prosthesis-related events (MAPEs) according to the guidelines for
reporting mortality and morbidity after cardiac valve intervention.12 Peri-
operative EOAIs were as anticipated by reference tables and individual
body surface area assessment. The follow-up EOAIs were determined by
echocardiographic measurement of the prosthesis valve area and individual
body surface area assessment.RESULTS
From January 2000 to December 2009, a total of 1864 pa-
tients underwent AVR at our institution. During the study
period, the number of AVRs increased from 173 in 2000
to 447 during 2009. A total of 440 patients were younger
than 60 years of age in the study period (biologic AVR
for 201 and mechanical AVR for 239).
The final study population consisted of 103 patients who
received a Carpentier-Edwards biologic AVR and 103 pa-
tients who received a mechanical AVR and constituted the
propensity-matched group. The preoperative patient charac-
teristics of both study groups are presented in Table 1. No
statistically significant differences were observed in the
matched parameters; however, age and the incidence of
acute aortic dissection differed between the 2 groups and
were adjusted for in the multivariate analysis. The mean
and median follow-up period was 33  24 and 29 months
(range, 2–120), respectively, and the survival status was
known for 97% of the patients. Complete echocardiographic
follow-up data were available for 78.3% of the patients. We
observed 12 events (deaths) per 548 patient-valve years.
The early outcomes did not significantly differ between the
2 groups. Five patients died within 90 days postoperatively ingery c November 2012
FIGURE 1. Flow chart of study population selection. AVR, aortic valve replacement; SJM, St Jude Medical; ATS, ATS Medical; CE, Carpentier-Edwards.
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Dthe biologic AVR group (1 patient died of multiorgan failure,
2 patients without special comorbidities died of sudden car-
diac arrest, and 2 patients died of prosthesis endocarditis).
More patients underwent reexploration for bleeding compli-
cations after mechanical AVR; however, this difference did
not reach statistical significance (17 [16.5%] vs 7 [6.8%];
P ¼ .052).
During the follow-up period (Figure 2), 10 patients who
had undergone biologic AVR died (0.05 death/patient-year)
compared with 2 patients who had undergone mechanical
AVR (0.009 death/patient-year). Cox proportional hazard
regression analysis suggested that patients who received
a biologic valves were more likely to die during follow-up
than those who received a mechanical valve (hazard ratio,
0.243; 95% confidence interval, 0.054–0.923; P ¼ .038;
Table 3). The cause of death in the biologic AVR group
was sudden cardiac death in 5 patients, as stated in the death
reports. Only 2 patients underwent an autopsy; 1 showed
endocarditis signs and a possible coronary embolization.
Another patient presented with an unknown advanced
lung tumor. The cause of death in the mechanical AVRThe Journal of Thoracic and Cargroup was hemorrhagic stroke in 1 and suicide in 1 patient.
Atrial fibrillation was reported more frequently in the
biologic AVR group (P ¼ .01), but MAPE did not seem
to differ between the study groups (Table 4). Freedom
from reoperation on the aortic valve did not differ between
the 2 groups (100% vs 98%; P ¼ .231). Only 2 patients—
both after mechanical AVR—required surgical repeat re-
placement of the prosthesis; both had developed prosthetic
valve endocarditis.
The echocardiographic follow-up examination was per-
formed at a mean interval of 21.8  19.8 months (range,
6–84) after AVR. Greater mean (11.2  4.2 mm Hg vs 10.2
 6.0 mm Hg, P ¼ .05) and peak (19.9  6.7 mm Hg vs
16.7  8.0 mm Hg, P ¼ .03) transvalvular aortic gradients
were detected in the biologic AVR group. Patients after me-
chanical AVR tended to have better left ventricular mass in-
dex regression (118.5  24.9 g/m2 vs 126.5  38.5 g/m2;
P¼ .056). Themean preoperative left ventricularmass index
was 165.57  56.8 g/m2 in the biologic AVR group and
170.33  51.44 g/m2 in the mechanical AVR group
(P ¼ .694). The amount of regression in each patient wasdiovascular Surgery c Volume 144, Number 5 1077
TABLE 1. Preoperative patient characteristics (paired analysis)
Perioperative patient
characteristics BP (n ¼ 103) MP (n ¼ 103) P value
Age (y) .029
Median 55 50
IQR 46–59 45–58
Male 86 (83.5) 87 (84.5) .612
NYHA functional
class III or IV
34 (33) 23 (22.3) .193
Smoking history 50 (48.5) 49 (47.6) .889
Diabetes 10 (9.7) 8 (7.8) .617
Renal failure 8 (7.8) 4 (3.9) .208
Endocarditis 9 (8.7) 7 (6.8) .617
Lung disease 9 (8.7) 8 (7.8) .808
Coronary heart disease 25 (24.3) 19 (18.4) .273
Peripheral vascular disease 3 (2.9) 0 (0) .083
Urgent or emergency status 10 (9.7) 14 (13.6) .277
Coronary artery bypass
grafting
23 (22.3) 18 (17.5) .465
Valve size (mm) .95
Median 25 25
IQR 23–27 23–27
Ejection fraction (%) .814
Median 60 60
IQR 50–65 50–65
Aortic valve insufficiency 81 (78.6) 72 (69.9) .139
None 22 (21.4) 31 (30.1)
Mild 27 (26.2) 12 (11.7)
Moderate 30 (29.1) 32 (31.1)
Severe 24 (23.3) 28 (27.2)
Aortic valve stenosis 60 (58.3) 44 (42.7) .238
None 43 (41.7) 59 (57.3)
Mild 7 (6.8) 5 (4.9)
Moderate 15 (14.6) 14 (13.6)
Severe 38 (36.9) 26 (25.2)
Previous cardiac surgery 7 (6.8) 11 (10.7) .454
Acute aortic dissection 1 (1.0) 10 (9.7) .007
Composite graft 22 (20.4) 34 (36.2) .181
Body surface area (m2) 1.9  0.17 1.9  0.22 1
Body mass index (kg/m2) .877
Median 25.6 26.4
IQR 23.18–28.24 22.99–29.73
Logistic euroScore .445
Median 4.65 4.65
IQR 2.27–8.96 2.27–10.05
ECC time (min) 113.13  62.04 106.13  51.07 .387
Crossclamp time (min) 80.61  34.34 76.24  31.71 .351
P values for paired analysis. BP, Bioprosthesis; MP, mechanical prosthesis; IQR, in-
terquartile range; NYHA, New York Heart Association; euroScore, European System
for Cardiac Operative Risk Evaluation; ECC, extracorporeal circulation.
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42.7 g/m2 in themechanicalAVRgroup (P¼ .291). Echocar-
diographically determined PPMwas more often observed in
patients after biologicAVR (EOAI, 0.876 0.219 cm2/m2 vs
EOAI, 1.11 0.39 cm2/m2,P¼ .01; Figure 3). Stratification
by PPM severity is listed in Table 5.1078 The Journal of Thoracic and Cardiovascular SurThe results of the questionnaire survey included infor-
mation about the different clinical practice between the 2
study groups. In our series, 81% of patients received spe-
cific information about the different valve types before their
index surgery admission and already had preferences for
the valve type that was finally implanted. Fourteen percent
of the patients received warfarin after biologic AVR, most
because of atrial fibrillation (Table 4). After mechanical
AVR, 3.2% of the patients were treated with a combination
of aspirin and clopidogrel only, and 1 patient received no
anticoagulation at all. In the biologic AVR group, only
57% of patients had received aspirin or clopidogrel at the
questionnaire survey, although 7.3% of the patients with
a mechanical valve had received combined therapy of war-
farin and aspirin or clopidogrel. However, the bioprosthetic
valve patients with oral anticoagulation for atrial fibrilla-
tion were more likely to survive during the follow-up pe-
riod, suggesting a protective effect of oral anticoagulation
(P ¼ .024).
DISCUSSION
The current guidelines for AVR do not consider patient
age as a major selection criterion for the decision regarding
which valve type should be recommended for AVR.1 Sev-
eral reasons support the increasing use of bioprosthetic
valves for AVR in the younger patient population aged 60
years or younger, including the better quality of life without
warfarin and without the perceptible noise of a mechanical
prosthesis, the excellent long-term durability of current tis-
sue valves with low rates of SVD, and the progress in anes-
thesiologic and surgical techniques with a accompanying
decrease in operative risk for redo-AVR procedures.3,13-15
In addition, the choice between a mechanical or tissue
valve in adults is also determined by estimating the
patient’s compliance with lifelong drug treatment and the
risk of anticoagulation-related bleeding and embolic events
with a mechanical valve versus the risk of SVDwith a tissue
valve. The possibility of treating tissue valve failure using
transcatheter valve-in-valve implantation might decrease
the risk of surgical reintervention, although current evi-
dence is lacking to consider it a valid alternative to surgery.
However, this option is currently frequently used by
cardiologists to convince younger patients of the benefits
of biologic valves.4,5,16
Long-term survival data from younger patients after bio-
logic versus mechanical AVR are rare and the relative risks
and benefits of biologic AVR in this population have not
been clearly determined.
The present propensity-matched study included 206
patients 60 years old or younger who underwent AVR
with bioprosthetic and mechanical valves. Our findings
were as follows. First, survival seemed better after mechan-
ical AVR. Second, mid-term echocardiographic studies
suggested—against our expectations—an early onset ofgery c November 2012
TABLE 2. Results of Cox regression analysis, accounting for matched design
Variable HR Robust SE z P>z 95% CI
Age 1.063 0.063 1.04 .297 0.9470–1.1951
Hypertension 0.9335984 0.7164458 0.09 .929 0.2074655–4.20121
Renal failure 3.475436 3.285754 1.32 .188 0.5448345–22.16941
Logistic euroScore 1.0218 0.0182618 1.04 .300 0.9828658–1.057604
ASA 3.450743 1.922925 2.22 .026 1.15766–10.28595
Active endocarditis 1.211325 1.402717 0.17 .869 0.1251894–11.7207
Acute aortic dissection 2.24e-20
Ejection fraction 1.0158 0.0241919 0.66 .509 0.9695078–1.064373
Functional 6.06e-21
AS 0.4628319 0.3402517 0.05 .295 0.1095622–1.955175
AI 9911871 0.9804856 0.01 .993 0.1426081–6.889173
Concomitant CABG 3.909154 2.816544 1.89 .059 0.9523407–15.98522
Type of aortic valve 0.2766136 0.2789901 1.27 .203 0.0383141–1.997046
NYHA 2.0081 0.9154 1.53 .126 0.8217568–4.907169
HR, Hazard ratio; SE, standard error; CI, confidence interval; euroScore, European System for Cardiac Operative Risk Evaluation; ASA, American Society of Anesthesiologists;
AS, aortic stenosis, AI, aortic insufficiency; CABG, coronary artery bypass grafting; NYHA, New York Heart Association.
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currence of moderate PPM. Finally, and more surprisingly,
the incidence of MAPEs or the need for reoperation was
comparable in both groups. Our results have confirmed
the findings of the most well-known randomized trial,
which showed better survival for patients after mechanical
AVR than for those with biologic AVR. The Department
of Veterans Affairs randomized trial17 revealed that the
use of mechanical valves in AVR resulted in a lower mortal-
ity rate, with the difference between biologic and mechan-
ical AVR becoming apparent after 10 years (66%  3% vs
79%  3%, P ¼ .02). In the second large historical trial
(Edinburgh Heart Valve Trial),18 a survival advantage for
mechanical valves was present at 12 years; however, the ac-
tuarial survival curves between the groups converged at 20
years of follow-up.FIGURE 2. A, Kaplan-Meier actuarial survival. B, Trunca
The Journal of Thoracic and CarRecently, an analysis of 41,227 patients after aortic valve
surgery from the Society for Cardiothoracic Surgery of
Great Britain and Ireland national database19 demonstrated
that the estimated survival of patients with a biologic valve
was significantly lower than that of patients with a mechan-
ical valve. The hazard ratio for improved survival was 1.46
(95% confidence interval, 1.35–1.57) if the patients had
received a mechanical aortic valve.
In contrast, a more recent prospective randomized trial by
Stassano and associates20 demonstrated a similar survival
rate 13 years after biologic or mechanical AVR. Random-
ized clinical trials represent the best evidence regarding
the risks and benefits for patients after implantation of bio-
logic or mechanical valves; however, as already emphasized
by others, randomization is a difficult task in such popula-
tions.20,21 In the present series, 81% of patients alreadyted curve at 10 patients. AVR, aortic valve replacement.
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TABLE 3. Odds ratios after bioprosthetic versus mechanical AVR
Variable Risk ratio 95% CI P value Risk ratio and 95% CI
Mortality, crude 0.243 0.064–0.923 .038
Mortality, adjusted for
EF, functional AI, CABG 0.240 0.058–0.995 .049
Active endocarditis, renal failure, dissection 0.283 0.075–1.065 .062
Age, hypertension, renal failure, log, euroScore, ASA
score, active endocarditis, aortic dissection, NYHA, EF,
functional status, CABG, AS, AI
0.277 0.038–1.997 .203
Effective orifice area index, crude 0.167 0.069–0.405 .000
0.01 0.1 1 10 100
Favors mechanical Favors biologic
Forest plot from univariate (‘‘crude’’) and multivariate Cox proportional hazard models that accounted for clustering of pair-matched patients to compare the effect of mechanical
versus biologic valve replacement therapy on overall survival and effective orifice area. P values were calculated using 2-sided Wald test derived from Cox proportional hazard
models. AVR,Aortic valve replacement; CI, confidence interval; EF, ejection fraction; AI, aortic insufficiency; CABG, coronary artery bypass grafting; ASA, American Society of
Anesthesiologists; NYHA, New York Heart Association; AS, aortic stenosis.
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Dhad a clear opinion concerning the choice of valve type at
admission for AVR surgery.
In a retrospective observational study from the Mayo
Clinic14 that focused on patients aged 50 to 70 years under-
going AVR, those with mechanical valves had a survival ad-
vantage compared with matched patients who received
bioprostheses. However, conflicting results have been re-
ported. Several retrospective studies could not demonstrate
differences in late survival when mechanical versus bio-
logic heart valves were compared.5,21,22-26
Although several studies presented data with longer
follow-up periods than in our study, most of these studies in-
cluded older patient populations. The mean age in our entire
study cohort was very young for choosing a tissue valve
(50.4  9.3 years), because age has been demonstrated to
be a very important factor when life expectancy after
AVR is concerned.27 In addition, several studies included
mixed various bioprosthetic valve types (eg, stented, stent-
less, porcine, and pericardial valves), which could have in-
troduced additional confounders because significant
differences in the SVD rate, survival, and echocardio-
graphic findings exist between the different valve types.28-34
Surprisingly, we observed a survival advantage for pa-
tients with a mechanical valves after a median interval of
only 3 years. This observation was unlikely to be a chance
finding. Considering most critically the lower age groups inTABLE 4. Outcomes at late follow-up (>90 days; those lost to follow-
up excluded)
Covariate BP (n ¼ 100) MP (n ¼ 100) P value
Late atrial fibrillation 12 2 .01
Late endocarditis 3 2 1
Late myocardial infarction 1 1 1
Late reoperation 0 2 .231
Late stroke 3 6 .316
Late cerebral hemorrhage 0 1 .482
Last NYHA class III or IV 4 4 .739
BP, Bioprosthesis; MP, mechanical prosthesis; NYHA, New York Heart Association.
1080 The Journal of Thoracic and Cardiovascular Surseveral long-term studies of bioprostheses (>50 years or
>60 years), an inflection point in the survival curve has con-
sistently been observed at 5 years after AVR.3,35,36
Other possible explanations for the observed difference in
the survival rates between the 2 groups should be consid-
ered: the observational retrospective character does not ex-
clude that patient characteristics not included in the
matching process could have importantly confounded the
results. For instance, patients who received a biologic
AVR were older (mean age, 55 years vs 50 years;
P ¼ .029) at implantation, and more urgent/emergent oper-
ations (including acute type A aortic dissection [1% vs
9.7%; P ¼ .007]) were performed in the group of patients
who underwent mechanical AVR. We tried to compensate
for the bias in patient selection by propensity matching pa-
tients with similar comorbidities and a similar extent of aor-
tic valve disease. However, this might not have excluded
and/or illustrated that bioprosthetic valves could haveFIGURE 3. Perioperative effective orifice area index (EOAI) anticipated
by reference tables and individual body surface area assessment (bio-
prosthesis [BP], 1.142  0.039 cm2/m2 vs mechanical prosthesis
[MP], 1.24  0.182 cm2/m2; P ¼ .599). Follow-up EOAI determined
by echocardiographic measurement of prosthesis valve area and individ-
ual body surface area assessment (BP, 0.876  0.219 cm2/m2 vs MP,
1.11  0.383 cm2/m2; P ¼ .01).
gery c November 2012
TABLE 5. EOAI at follow-up (echocardiographic measurements)
Severity of PPM
after AVR EOAI (cm2/m2) BP (%) MP (%) P value
Mild >0.9 48.8 63.9 NS
Moderate >0.6–0.9 37.3 35.1 NS
Severe 0.6 13.9 0 .01
EOAI, Effective orifice area index; PPM, prosthesis–patient mismatch; AVR, aortic
valve replacement; BP, bioprosthesis; MP, mechanical prosthesis.
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peared to be more ill and therefore to have a less favorable
life expectancy. This hypothesis might even be supported
by the fact that during follow-up, more patients in the bio-
logic AVR group had atrial fibrillation, which might be
a sign of advanced cardiac disease37; however, these pa-
tients, of all of the patients, enjoyed a protective effect
from oral anticoagulation with regard to early and late sur-
vival (P¼ .024). In contrast, several younger and physically
active patients requested a biologic AVR to avoid lifelong
warfarin therapy.
In our clinical practice, patients with aortic valve biopros-
theses and sinus rhythm receive lifelong aspirin only as an-
tithrombotic treatment. However, in the present study, up to
14% of patients after bioprosthetic AVRwere receiving oral
anticoagulation to treat atrial fibrillation. This group of pa-
tients presented with 100% late survival. This finding and
the better survival of patients with mechanical valves might
suggest a potential protective effect of oral anticoagulation,
regardless of the valve type in these young patients. Despite
the guidelines issued by several professional societies, the
opinions and medical practices related to the prevention
of thrombotic events early after implantation of aortic
bioprostheses remain conflicting.38-40 In addition, the need
or not for anticoagulation after bioprosthetic AVR was
determined mostly from series with patients older than 60
years.
The risk of SVD is clearly greater for biologic than for
mechanical valve prostheses. Patient age at AVR is the
most important determinant of SVD during follow-up.27 It
has been demonstrated21 that the risk of major bleeding
after mechanical AVR equals the risk of reoperation after
biologic AVR in patients aged 60 years at surgery. Despite
the excellent long-term follow-up data generated for differ-
ent types of tissue valves, it cannot be emphasized strongly
enough that premature onset of SVD dramatically increases
the younger the patient population. In their report on 18
years’ experience with the Perimount xenopericardial tissue
valve, Aupart and associates41 showed freedom from SVD
at late follow-up of 99%  1% in patients aged 70 years
but as low as 45% 15% in patients younger than 60 years.
In the present study, no reoperation was performed because
of SVD, mainly owing to the limited observation interval.
Because it was clear that we would not see many cases of
classic SVD, we focused on the early to mid-termThe Journal of Thoracic and Carechocardiographic findings42-44 and were surprised to
observe considerably poorer EOAI values at a mean of
21.8  19.8 months in the younger patients after biologic
AVR. Because we had adopted a strategy to avoid
implantation of valves sized smaller than 21 mm, we
expected a minimum of PPM immediately after AVR. In
those cases that do not fulfill a minimal size of the
annulus of 21 mm, we perform annulus enlargement. All
patients in the present trial had a theoretical EOAI of 0.9
cm2/m2 or greater at implantation (as anticipated by the
reference tables). However, it is still possible that the
EOAI values might have been worse than expected at
surgery, although the observation that EOAI became more
narrowed during follow-up might have been a sign of sub-
clinical SVD. Longer echocardiographic follow-up exami-
nations are necessary to elucidate this issue.
Finally, when MAPE are considered, no major difference
was seen in the incidence of bleeding events between the 2
groups. The younger age of our patients, the introduction of
point of care devices with home international normalized
ratio monitoring, and the close patient–physician relation-
ship present in our country might have potentially resulted
in lower levels of anticoagulation and therefore decreased
the bleeding risk.30 The potential of new oral direct
thrombin-inhibitors (Rivaroxaban, Dabigatran) as a substi-
tute for warfarin for patients with mechanical valves will be
explored in the future.
In agreement with other studies,17,18 no difference was
found in late thromboembolism between patients with
mechanical valves and those with bioprosthetic valves.
Transcatheter aortic valve implantation (TAVI) has
emerged as an attractive less-invasive treatment option for
patients with symptomatic severe aortic valve stenosis. Cur-
rently, patients thought to be at excessive risk of conven-
tional surgical AVR are considered candidates for TAVI.
These patients are typically elderly patients with significant
comorbidities, usually reflected by a logistic European Sys-
tem for Cardiac Operative Risk Evaluation of more than
20% or a Society of Thoracic Surgeons risk of mortality
of greater than 10% for perioperative mortality. Patients
with other factors that increase surgical risk but not cap-
tured by these scoring system (eg, porcelain aorta, previous
chest radiation, general frailty) are also deemed appropriate
candidates for TAVI. In the most recent period, patients with
degeneration of previously implanted tissue valves could
also potentially benefit from beating-heart TAVI, eliminat-
ing the risks associated with the use of cardiopulmonary
bypass and cardiac arrest—even if protected by myocardial
protection solutions. Previous animal studies and selected
clinical case series have suggested that valve-in-valve
TAVI for degenerated bioprostheses is technically feasible
and safe. However, the small number of patients undergoing
valve-in-valve TAVI reported to date, even at pioneering
centers, precludes reliable insights into the clinical successdiovascular Surgery c Volume 144, Number 5 1081
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Dand complication rates of valve-in-valve TAVI. This proce-
dure can be performed with high technical success and ex-
cellent postprocedural function of the stented valve;
however, in these elderly high-risk patients with multiple
comorbidities, valve-in-valve TAVI was associated with
17% mortality, mostly from septic complications.16 Many
efforts to improve technology, along with better periopera-
tivemanagement, will most probably improve the outcomes
of valve-in-valve TAVI in these very high-risk patients.
The limitations of the present trial included that it was
a retrospective analysis and as such was subject to selection
bias. We tried to compensate for the bias in patient selection
by propensity matching patients with similar comorbidities
and a similar extent of aortic valve disease. Most impor-
tantly, individual matching and analysis plans were agreed
on before the data were inspected; thus, we were unaware
of the outcomes before the comparison groups were estab-
lished. However, longer and more complete follow-up with
echocardiographic examination is mandatory to confirm our
findings.
In conclusion, the present trial adds some practical
knowledge regarding the choice of the valve type in patients
younger than 60 years of age who require AVR. We ob-
served better survival of patients who received mechanical
prostheses in this age group. The implantation of a biologic
valve in aortic position in those younger than 60 years
seemed to increase the adjusted mortality risk. We have
concluded that the evidence is as yet insufficient to recom-
mend bioprosthetic valves, other than in exceptional situa-
tions, for younger patients (<60 years) who require AVR.
Larger prospective randomized trials are needed to explore
these results in more detail. For instance, we suggest a strict
randomization between only 2 valves types in isolated AVR
and a longer continued echocardiographic analysis of the
prosthetic valve areas.
References
1. BonowRO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the
management of patients with valvular heart disease. J Am Coll Cardiol. 2006;48:
e1-148. erratum in J Am Coll Cardiol.2007;49:1014.
2. Brown JM, O’Brien SM, Wu Ch, Sikora JA, Griffith BP, Gammie JS. Isolated
aortic valve replacement in North America comprising 108687 patients in 10
years: changes in risks, valve types, and outcomes in the Society of Thoracic Sur-
geons National Database. J Thorac Cardiovasc Surg. 2009;137:82-90.
3. McClure RS, Narayanasamy N, Wiegerinck E, Lipsitz S, Maloney A, Byrne JG,
et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards
pericardial bioprosthesis: up to 17-year follow-up in 1000 patients. Ann Thorac
Surg. 2010;89:1410-6.
4. Olsen LK, Engstrom T, Sndergaard L. Transcatheter valve-in-valve implantation
due to severe aortic regurgitation in a degenerated aortic homograft. J Invasive
Cardiol. 2009;21:E197-200.
5. Ruel M, Chan V, Bedard P, et al. Very long-term survival implications of heart
valve replacement with tissue versus mechanical prostheses in adults<60 years
of age. Circulation. 2007;116:I295-300.
6. Carpentier A. The surprising rise of nonthrombogenic valvular surgery.Nat Med.
2007;13(10):1165-8.
7. Seiffert M, Franzen O, Conradi L, et al. Series of transcatheter valve-in-valve
implantations in high-risk patients with degenerated bioprostheses in aortic
and mitral position. Catheter Cardiovasc Interv. 2010;76:608-15.1082 The Journal of Thoracic and Cardiovascular Sur8. Bergstralh EJ, Konsanke JL. Computerized matching of cases to controls. Tech-
nical Report 56. Department of Health Science Research. Rochester, MN: Mayo
Clinic; 1995.
9. Heinze G, Juni P. An overview of the objectives of and the approaches to propen-
sity score analyses. Eur Heart J. 2011;32:1704-8.
10. Rubin DB. The design versus the analysis of observational studies for causal ef-
fects: parallels with the design of randomized trials. Stat Med. 2007;26:20-36.
11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observa-
tional studies for causal effects. Biometrika. 1983;70:41-55.
12. Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and
morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 2008;
135:732-8.
13. Christiansen S, Schmid M, Autschbach R. Perioperative risk of redo aortic valve
replacement. Ann Thorac Cardiovasc Surg. 2009;15:105-10.
14. BrownML, SchaffHV, Lahr BD,MullanyCJ, Sundt TM,Dearani JA, et al. Aortic
valve replacement in patients aged 50 to 70 years: improved outcome with me-
chanical versus biologic prostheses. J ThoracCardiovasc Surg. 2008;135:878-84.
15. Aymard T, Eckstein F, Englberger L, Stalder M, Kadner A, Carrel T. The Sorin
Freedom SOLO stentless aortic valve: technique of implantation and operative
results in 109 patients. J Thorac Cardiovasc Surg. 2010;139:775-7.
16. Eggebrecht H, Sch€afer U, Treede H, Boekstegers P, Babin-Ebell J, Ferrari M,
et al. Valve-in-valve transcatheter aortic valve implantation for degenerated bio-
prosthetic heart valves. JACC Cardiovasc Interv. 2011;4:1218-27.
17. Hammermeister KE, Sethi GK, Henderson WC, et al. Outcomes 15 years after
valve replacement with a mechanical versus bioprosthetic valve: final report of
the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152-8.
18. Oxenham H, Bloomfield P, Wheatly DJ, et al. Twenty year comparison of
a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart.
2003;89:715-21.
19. Dunning J, Gao H, Chambers J, Moat N, Murphy G, Pagano D, et al. Aortic valve
surgery: marked increases in volume and significant decreases in mechanical
valve use–an analysis of 41,227 patients over 5 years from the Society for Car-
diothoracic Surgey in Great Britain and Ireland National database. J Thorac Car-
diovasc Surg. 2011;142:776-82.e3.
20. Stassano P, Di Tommaso L, Monaco M, et al. Aortic valve replacement: a pro-
spective randomized evaluation of mechanical versus biological valves in
patients ages 55 to 70 years. J Am Coll Cardiol Intv. 2009;54(20):1862-8.
21. van Geldorp MWA, Jamieson RE, Kappetein AP, Ye J, Fradet GJ,
Eijkemenas MJC, et al. Patient outcome after aortic valve replacement with a me-
chanical or biological prosthesis: weighing lifetime anticoagulant-related event
risk against reoperation risk. J Thorac Cardiovasc Surg. 2009;137:881-6.
22. Ruel M, Kulik A, Lam B, et al. Long-term outcomes of valve replacement with
modern prostheses in young adults. Eur J Cardiothorac Surg. 2005;27:425-33.
23. Kahn SS, Trento A, DeRobertis M, et al. Twenty-year comparison of tissue and
mechanical valve replacement. J Thorac Cardiovasc Surg. 2001;122:257-69.
24. Chan V, Jamieson WR, Germann E, et al. Performance of bioprostheses and me-
chanical prostheses assessed by composites of valve-related complications to 15
years after aortic valve replacement. J ThoracCardiovasc Surg. 2006;131:1267-73.
25. Kulik A, Bedard P, LamBK, et al. Mechanical versus bioprosthetic valve replace-
ments in middle-aged patients. Eur J Cardiothorac Surg. 2006;30:485-91.
26. Prasongsukarn K, Jamieson WR, Lichtenstein SV. Performance of bioprostheses
and mechanical prostheses in age group 61–70 years. J Heart Valve Dis. 2005;14.
501-501.
27. Rahimtoola AH. Choice of prosthetic heart valve in adults: an update. J Am Coll
Cardiol. 2010;55(22):2413-26.
28. Marquez S, Hon RT, Yoganathan AP, et al. Comparative hydrodynamic evalua-
tion of bioprosthetic heart valves. J Heart Valv Dis. 2001;10:802-11.
29. Bottio T, Caprilio L, Casarotto D, et al. Small aortic annulus: the hemodynamic
performances of 5 commercially available bileaflet valves. J Thorac Cardiovasc
Surg. 2004;128:457-62.
30. Kuehnel R-U, Puchner R, Pohl A, et al. Characteristics resistance curves of aortic
valve substitutes facilitate individualized decision for a particular patient. Eur J
Cardiothorac Surg. 2005;27:450-5.
31. Rahimtoola SH. The year in valvular heart disease. J Am Coll Cardiol. 2006;47:
427-39.
32. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation
of prosthetic valves with echocardiography and Doppler ultrasound. J Am Soc
Endocardiogr. 2009;22:975-1014.
33. Cohen G, Christakis GT, Joyner CD, et al. Are stentless valves hemodynamically
superior to stented valves? A prospective randomized trial. Ann Thorac Surg.
2002;73:767-78.gery c November 2012
Weber et al Acquired Cardiovascular Disease
A
C
D34. Chambers JB, Rimington HM, Hodson F, et al. The subcoronary Toronto stent-
less versus supra-annular Perimount stented replacement aortic valves: early
clinical and hemodynamic results of a randomized comparison in 160 patients.
J Thorac Cardiovasc Surg. 2006;131:878-82.
35. Biglioli P, Spampinato N, Cannata A, et al. Long-term outcomes of the
Carpentier-Edwards pericardial valve prosthesis in the aortic position: effect of
patient age. J Heart Valve Dis. 2004;13(Suppl):49-51.
36. Banbury MK, Cosgrove DM, White JA, Blackstone EH, Frater RWM, Okies JE.
Age and valve size effect on the long-term durability of the Carpentier-Edwards
aortic pericardial bioprosthesis. Ann Thorac Surg. 2001;72:753-7.
37. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D.
Impact of atrial fibrillation on the risk of death: the Framingham heart study.
Circulation. 1998;98:946-52.
38. Colli A, Verhoye JP, Leguerrier A, Gherli T. Anticoagulation or antiplatelet ther-
apy of bioprosthetic heart valves recipients: an unresolved issue. Eur J Cardio-
thorac Surg. 2007;31:573-7.The Journal of Thoracic and Car39. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early
antithrombotic therapy necessary in patients with bioprosthetic aortic valves in
normal sinus rhythm? J Thorac Cardiovasc Surg. 2010;139:1137-45.
40. Aramendi JI, Mestres CA. Antithrombotic therapy after bioprosthetic aortic
valve replacement. Eur J Cardiothorac Surg. 2008;33:529-30.
41. Aupart MR, Mirza A, Meurisse YA, et al. Perimount pericardial bioprosthesis for
aortic calcified stenosis: 18-year experience with 1133 patients. J Heart Valve
Dis. 2006;15:768-76.
42. Mohty D, Dumesnil JG, Echahidi N, et al. Impact of prosthesis patient mismatch
on long-term survival after aortic valve replacement: influence of age, obesity
and left ventricular dysfunction. J Am Coll Cardiol. 2009;53:39-47.
43. Rahimtoola SH. The year in valvular heart disease. J Am Coll Cardiol. 2010;
55(16):1749-52.
44. Wyss TR, Bigler M, Stalder M, et al. Absence of prosthesis-patient mismatch
with the new generation of Edwards stented aortic bioprosthesis. Interact Cardi-
ovasc Thorac Surg. 2010;10:884-7.diovascular Surgery c Volume 144, Number 5 1083
